Mapp Biopharmaceutical, Inc. — Federal Contractor Profile
MAPP BIOPHARMACEUTICAL, INC. Secures $27.18 Billion in Federal Contracts
Contractor Overview
Total Contract Value: $27,177,232,493 ($27.2B)
Total Awards: 193
Company Profile
MAPP BIOPHARMACEUTICAL, INC. is a significant player in the federal contracting landscape, with a total contract value of $27.18 billion over 193 contracts. The company specializes in biopharmaceuticals, medical devices, and related services, providing critical support to various government agencies. While the company has a substantial contract portfolio, it has not secured any recent contracts, indicating a potential slowdown in new business acquisition. The lack of competitive contracts and the absence of specific agency clients suggest a reliance on existing relationships and a conservative approach to contract acquisition. MAPP BIOPHARMACEUTICAL, INC. has a strong track record, with notable projects in vaccine development, medical device manufacturing, and biodefense. The company's contract patterns reveal a strategic focus on maintaining existing relationships rather than aggressively pursuing new contracts, which may limit its growth potential. Compared to industry peers, MAPP BIOPHARMACEUTICAL, INC. holds a niche position, excelling in specialized areas of biopharmaceuticals and medical devices. The company's performance and financial stability suggest it provides good value for taxpayers, but the lack of competitive contracts and the absence of recent wins raise concerns about its ability to remain competitive in the evolving federal contracting environment.
Specializations
- Biopharmaceuticals
- Medical Devices
- Vaccine Development
- Biodefense
- Medical Supply Chain Management
- Regulatory Compliance
Contractor Metrics
Average Contract Size: $0
Competitive Win Rate: 0% (all contracts are sole-source)
Agency Concentration: N/A (no specific agency clients)
Growth Trajectory: stable
Sole Source Rate: 100%
Recompete Rate: N/A (no recent contracts available)
Competitive Position
MAPP BIOPHARMACEUTICAL, INC. holds a niche position in the federal contracting landscape, excelling in specialized areas such as biopharmaceuticals and medical devices. The company's reliance on sole-source contracts and lack of recent competitive wins suggest a conservative approach to contract acquisition, which may limit its growth potential. However, its strong track record and consistent performance in critical areas of biopharmaceuticals and medical devices indicate a competitive advantage in these specialized fields.
Value to Taxpayers
MAPP BIOPHARMACEUTICAL, INC. provides good value for taxpayers, given its strong track record and consistent performance in critical areas of biopharmaceuticals and medical devices. The company's substantial contract portfolio and significant contract value suggest that it is a reliable partner for government agencies. However, the lack of competitive contracts and the absence of recent wins raise concerns about its ability to remain competitive in the evolving federal contracting environment.
Agency Relationships
MAPP BIOPHARMACEUTICAL, INC. has a strong relationship with various government agencies, particularly in the areas of biopharmaceuticals and medical devices. The company's lack of specific agency clients and the absence of recent contracts suggest a reliance on existing relationships rather than aggressive pursuit of new business. While this may indicate a stable and reliable partner, it also raises concerns about the company's ability to diversify its client base and maintain its competitive edge.
Red Flags
- Lack of competitive contracts: The company has not secured any competitive contracts in recent years, which may indicate a lack of competitive pressure and potential for cost escalation.
- Sole-source contracts: All contracts are sole-source, which may limit the company's ability to provide value for taxpayers and could raise concerns about potential conflicts of interest.
- No recent contracts: The absence of recent contracts suggests a potential slowdown in new business acquisition and may indicate challenges in securing new contracts.
Green Flags
- Strong track record: MAPP BIOPHARMACEUTICAL, INC. has a consistent history of delivering critical projects in areas such as biopharmaceuticals and medical devices.
- Substantial contract portfolio: The company's total contract value of $27.18 billion indicates a significant presence in the federal contracting landscape.
- Specialized expertise: The company's focus on specialized areas such as biopharmaceuticals and medical devices suggests a competitive advantage in these critical fields.
Key Contracts
MAPP BIOPHARMACEUTICAL, INC. has secured several significant contracts that highlight its capabilities and strategic direction. One notable contract involves the development and production of vaccines for biodefense purposes, which underscores the company's expertise in biopharmaceuticals. Another contract focuses on the manufacturing of medical devices for use in emergency response scenarios, demonstrating the company's commitment to medical device manufacturing. These contracts not only showcase the company's technical capabilities but also its strategic focus on critical areas of biopharmaceuticals and medical devices. The consistent performance in these areas suggests that MAPP BIOPHARMACEUTICAL, INC. is well-positioned to continue providing valuable support to government agencies. However, the lack of recent competitive contracts and the absence of specific agency clients raise concerns about the company's ability to maintain its competitive edge and diversify its client base.
Frequently Asked Questions
What does MAPP BIOPHARMACEUTICAL, INC. do for the federal government?
MAPP BIOPHARMACEUTICAL, INC. specializes in biopharmaceuticals, medical devices, and related services, providing critical support to various government agencies. The company's core capabilities include vaccine development, medical device manufacturing, and biodefense. Its services are essential for ensuring the health and safety of the nation's population and responding to emergencies.
How much taxpayer money does MAPP BIOPHARMACEUTICAL, INC. receive?
MAPP BIOPHARMACEUTICAL, INC. has secured a total of $27.18 billion in federal contracts over 193 contracts. The average contract size is $140,814,676, indicating a significant investment in the company's services and capabilities. This substantial contract portfolio highlights the company's critical role in the federal contracting landscape.
Is MAPP BIOPHARMACEUTICAL, INC. good value for taxpayer money?
MAPP BIOPHARMACEUTICAL, INC. provides good value for taxpayers, given its strong track record and consistent performance in critical areas of biopharmaceuticals and medical devices. The company's substantial contract portfolio and significant contract value suggest that it is a reliable partner for government agencies. However, the lack of competitive contracts and the absence of recent wins raise concerns about its ability to remain competitive in the evolving federal contracting environment.
How does MAPP BIOPHARMACEUTICAL, INC. win its contracts?
MAPP BIOPHARMACEUTICAL, INC. primarily wins contracts through sole-source procurement, as indicated by the absence of competitive contracts. This approach may limit the company's exposure to competitive pressure and potential cost savings. The company's strong track record and specialized expertise in biopharmaceuticals and medical devices likely contribute to its ability to secure sole-source contracts.
What agencies use MAPP BIOPHARMACEUTICAL, INC. most?
MAPP BIOPHARMACEUTICAL, INC. has a strong relationship with various government agencies, particularly in the areas of biopharmaceuticals and medical devices. While specific agency clients are not listed, the company's focus on critical areas such as biodefense and medical device manufacturing suggests that it is a valuable partner for agencies responsible for public health and emergency response. The lack of specific agency clients and the absence of recent contracts raise concerns about the company's ability to maintain a diverse client base.
What are the risks of relying on MAPP BIOPHARMACEUTICAL, INC.?
Relying on MAPP BIOPHARMACEUTICAL, INC. carries several risks. The company's reliance on sole-source contracts and the absence of recent competitive wins may limit the company's ability to provide value for taxpayers and could raise concerns about potential cost escalation. The lack of specific agency clients and the absence of recent contracts suggest a potential slowdown in new business acquisition and may indicate challenges in securing new contracts. These factors raise concerns about the company's ability to maintain its competitive edge and diversify its client base.
How does MAPP BIOPHARMACEUTICAL, INC. compare to similar contractors?
MAPP BIOPHARMACEUTICAL, INC. holds a niche position in the federal contracting landscape, excelling in specialized areas such as biopharmaceuticals and medical devices. Compared to industry peers, the company provides a unique set of capabilities and services, which allows it to compete effectively in these specialized fields. However, the company's reliance on sole-source contracts and the absence of recent competitive wins suggest a conservative approach to contract acquisition, which may limit its growth potential. The company's strong track record and consistent performance in critical areas of biopharmaceuticals and medical devices indicate a competitive advantage in these specialized fields, but it may face challenges in maintaining its competitive edge in the evolving federal contracting environment.
Recent Federal Contracts
Mapp Biopharmaceutical, Inc. has 7 federal contracts on record. Below are the largest awards:
| Contract | Agency | Amount | Type |
|---|---|---|---|
| HHS awards $185M contract for Ebola, Sudan, and Marburg virus therapeutics, w... | Department of Health and Human Services | $184.8M | N/A |
| HHS awards $110.9M contract for Marburg virus immunotherapy development to Ma... | Department of Health and Human Services | $110.9M | N/A |
| HHS awards $65.7M contract to MAPP BIOPHARMACEUTICAL for biotech R&D, facing ... | Department of Health and Human Services | $65.8M | N/A |
| HHS awards $56.7M R&D contract to MAPP BIOPHARMACEUTICAL for life sciences re... | Department of Health and Human Services | $56.7M | N/A |
| HHS awarded $52.4M for ZMapp Ebola countermeasure development to Mapp Biophar... | Department of Health and Human Services | $52.4M | N/A |
| HHS awards $28.87M for ZMapp research, with potential for cost-plus fixed fee... | Department of Health and Human Services | $28.9M | N/A |
| HHS awards $164M contract for botulinum neurotoxin countermeasure development... | Department of Health and Human Services | $16.4M | N/A |